{"doi":"10.1101/2021.07.19.452771","title":"Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants","abstract":"Abstract The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine efficacy. Here, neutralizing antibody titers elicited by mRNA-based and an adenoviral vector-based vaccine against variant pseudotyped viruses were compared. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals were of low neutralizing titer (IC 50 <50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest the benefit of a second immunization following Ad26.COV2.S to increase protection against the variants.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2021,"id":212804,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":110,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9521,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":661704,"name":"Hao Zhou","orcid":"0000-0002-0092-7987","position":1,"is_corresponding":false},{"id":550603,"name":"Marie I. Samanovic","orcid":"0000-0002-6987-2232","position":2,"is_corresponding":false},{"id":292174,"name":"Belinda M. Dcosta","orcid":"0000-0001-8497-4942","position":3,"is_corresponding":false},{"id":710782,"name":"Amber Cornelius","orcid":null,"position":4,"is_corresponding":false},{"id":3883,"name":"Mark J. Mulligan","orcid":"0000-0001-7262-9746","position":5,"is_corresponding":false},{"id":16989,"name":"Nathaniel R. Landau","orcid":"0000-0002-9997-1004","position":6,"is_corresponding":false},{"id":16988,"name":"Takuya Tada","orcid":"0000-0003-0779-9954","position":0,"is_corresponding":true}],"reference_count":26,"raw_metadata":null,"created_at":"2026-07-18T23:52:31.378994Z","pmid":"34312623","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}